Danaher (NYSE:DHR) Releases Earnings Results, Beats Expectations By $0.14 EPS

Danaher (NYSE:DHR) announced its earnings results on Tuesday. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14, Briefing.com reports. The company had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. Danaher’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.02 earnings per share.

Danaher Trading Up 0.3 %

Shares of NYSE DHR traded up $0.79 during mid-day trading on Friday, hitting $248.79. The company’s stock had a trading volume of 231,880 shares, compared to its average volume of 2,728,596. Danaher has a one year low of $182.09 and a one year high of $281.70. The stock has a market cap of $184.28 billion, a price-to-earnings ratio of 42.01, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The company’s fifty day simple moving average is $270.43 and its 200-day simple moving average is $260.43.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be issued a dividend of $0.27 per share. The ex-dividend date is Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.43%. Danaher’s dividend payout ratio is currently 18.31%.

Insider Activity at Danaher

In other Danaher news, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the transaction, the chief financial officer now directly owns 29,407 shares in the company, valued at approximately $8,229,254.88. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Matthew Mcgrew sold 16,172 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total value of $4,525,572.48. Following the transaction, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at approximately $8,229,254.88. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 30,059 shares of company stock worth $8,400,897 in the last quarter. Corporate insiders own 11.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on DHR shares. Barclays cut their target price on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a research report on Wednesday. TD Cowen lifted their price objective on Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research report on Wednesday. The Goldman Sachs Group raised their price target on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Leerink Partners increased their price objective on Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Finally, Evercore ISI increased their target price on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Seven investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $287.28.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.